Detection of doxorubicin in the horny layer in a patient suffering from Palmar-plantar erythrodysaesthesia [1]

Dermatology

Volumn 210, Issue 3, 2005, Pages 237-238

  Schmook, Tobias ^a   Jacobi, Ute ^a   Lademann, Jürgen ^a   Worm, Margitta ^a   Stockfleth, Eggert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chromophore, tetracyclic; Liposomal encapsulated doxorubicin; Palmar plantar erythrodysaesthesia

Indexed keywords

CLOBETASOL PROPIONATE; DOXORUBICIN;

ADULT; ANAMNESIS; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CASE REPORT; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LETTER; LYMPHANGIOSARCOMA; PRIORITY JOURNAL; REMISSION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DOXORUBICIN; FEMALE; FOOT DERMATOSES; HUMANS; MIDDLE AGED; PARESTHESIA;

EID: 17244370519     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083794     Document Type: Letter

References (14)

1. Crawford JH, Eikelboom JW, McQuillan A: Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukaemia. Eur J Haematol 2002;69:315-317.
2. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, Von Roenn J: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169-2173.
3. Iurlo A, Fornier M, Caldiera S, Bertoni F, Foa P: Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy - An underestimated toxic event? Acta Oncol 1997;36:653-654.
4. Rios-Buceta L, Buezo GF, Penas PF, Dauden E, Fernandez-Herrera J, Garcia-Diez A: Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with tegafur. Acta Derm Venereol 1997; 77:80-81.
5. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A: Skin toxic effects of glycol-coated liposomal doxorubicin. Arch Dermatol 2001;137:1528-1529.
6. Sharpe M, Easthope SE, Keating GM, Lamb HM: Polyethylene glycolliposomal doxorubicin: A review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002;62:2089-2126.
7. Gabizon A, Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin: Rationale for use in solid tumors. Drugs 1997;54:15-21.
8. de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G, Sparreboom A: Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 1999;266:216-221.
9. Jacobi U, Waibler E, Bartoll J, Schulze P, Sterry W, Lademann J: In vivo determination of doxorubicin and its metabolites within the skin using laser scanning microscopy. Laser Phys Lett 2004;2:100-104.
10. Hwang K, Baik SH: Distribution of hairs and sweat glands on the bodies of Korean adults: A morphometric study. Acta Anat 1997;158:112-120.
11. Ya-Xian Z, Suetake T, Tagami H: Number of cell layers of the stratum corneum in normal skin - Relationship to the anatomical location on the body, age, sex and physical parameters. Arch Dermatol Res 1999;291:555-559.
12. Hu CH: Sweat-related dermatoses: Old concept and new scenario. Dermatologica 1991;182:73-76.
13. Horn TD: Antineoplastic chemotherapy, sweat, and the skin. Arch Dermatol 1997;133:905-906.
14. Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J: Variations of hair follicle size and distribution in different body sites. J Invest Dermatol 2004;122:14-19.